Emerging COVID-19 variant s have encouraged many biotech giants to actively participate in developing microfluidic devices for rapid and accurate SARS-CoV-2 detection. Though the current global wave of the omicron COVID-19 variant is relatively mild in terms of causing severe disease and death, it's necessary to continuously develop new technologies and strategies to identify and resist COVID-19 infection in case more aggressive variants may come around from nowhere. Microfluidics, a highly miniaturized, automatic, and integrated technology, is expecte d to perform rapid, low-cost, accurate, and point-of-care detection of infectious diseases like COVID-19. Researchers from leading life science companies like Creative Biolabs have gotten involved in developing and designing microfluidic devices for different applications, including devices for quick and accurate SARS-CoV-2 detection. Microfluidic Chips for Pathogen Detection Infectious disea...